0001493152-26-013850 | 10-K | XBRL Viewer

Print Document

SUMMARY OF STOCK OPTIONS OUTSTANDING (Details)	12 Months Ended
SUMMARY OF STOCK OPTIONS OUTSTANDING (Details)	Dec. 31, 2025 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number \| shares	18,695
Options Exercisable, Number \| shares	11,011
Exercise Price One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, Upper	$ 9.20
Options Outstanding, Number \| shares	14,485
Options Outstanding, Weighted Average Remaining Contractual Term (in years)	9 years 7 months 6 days
Options Outstanding, Weighted Average Exercise Price	$ 9.20
Options Exercisable, Number \| shares	7,252
Options Exercisable, Weighted Average Remaining Contractual Term (in years)	9 years 7 months 6 days
Options Exercisable, Weighted Average Exercise Price	$ 9.20
Exercise Price Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, Upper	$ 19.80
Options Outstanding, Number \| shares	2,404
Options Outstanding, Weighted Average Remaining Contractual Term (in years)	8 years 3 months 18 days
Options Outstanding, Weighted Average Exercise Price	$ 15.93
Options Exercisable, Number \| shares	1,953
Options Exercisable, Weighted Average Remaining Contractual Term (in years)	8 years 3 months 18 days
Options Exercisable, Weighted Average Exercise Price	$ 16.09
Range of Exercise Prices, Lower	9.21
Exercise Price Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, Upper	$ 19.80
Options Outstanding, Number \| shares	1,806
Options Outstanding, Weighted Average Remaining Contractual Term (in years)	5 years 6 months
Options Outstanding, Weighted Average Exercise Price	$ 67.28
Options Exercisable, Number \| shares	1,806
Options Exercisable, Weighted Average Remaining Contractual Term (in years)	5 years 6 months
Options Exercisable, Weighted Average Exercise Price	$ 67.28

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
Cybersecurity Risk Management and Strategy Disclosure	Dec. 31, 2025
Cybersecurity Risk Management, Strategy, and Governance [Abstract]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	CYBERSECURITYWe have processes for assessing, identifying and managing cybersecurity risks, which are built into our information technology (“IT”) function and are designed to help protect our information assets and operations from internal and external cyber threats, protect employee and clinical trial information from unauthorized access or attack, as well as secure our networks and systems. Such processes include physical, procedural, and technical safeguards, response plans, and routine review of our policies and procedures to identify risks and refine our practices. We engage certain external parties, including a full-service managed IT service provider, to enhance our cybersecurity oversight. Our Audit Committee of the Board of Directors (the “Audit Committee”) is responsible for overseeing cybersecurity risk and periodically updates our Board of Directors on such matters. The Audit Committee receives periodic updates from management regarding cybersecurity matters and is notified between such updates regarding any significant new cybersecurity threats or incidents. We do not believe that there are currently any known risks from cybersecurity threats that are reasonably likely to materially affect us or our business strategy, results of operations or financial condition. Management is responsible for the operational oversight of company-wide cybersecurity strategy, policy, and standards across relevant departments to assess and help prepare us to address cybersecurity risks. In an effort to deter and detect cyber threats, we annually provide all employees with cybersecurity and prevention training, which covers timely and relevant topics, including social engineering, phishing, password protection, confidential data protection, and mobile security, and educates employees on the importance of reporting all incidents immediately. We also use technology-based tools to mitigate cybersecurity risks and to bolster our employee-based cybersecurity programs.
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	We have processes for assessing, identifying and managing cybersecurity risks, which are built into our information technology (“IT”) function and are designed to help protect our information assets and operations from internal and external cyber threats, protect employee and clinical trial information from unauthorized access or attack, as well as secure our networks and systems. Such processes include physical, procedural, and technical safeguards, response plans, and routine review of our policies and procedures to identify risks and refine our practices.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]	We do not believe that there are currently any known risks from cybersecurity threats that are reasonably likely to materially affect us or our business strategy, results of operations or financial condition.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	Our Audit Committee of the Board of Directors (the “Audit Committee”) is responsible for overseeing cybersecurity risk and periodically updates our Board of Directors on such matters. The Audit Committee receives periodic updates from management regarding cybersecurity matters and is notified between such updates regarding any significant new cybersecurity threats or incidents.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	Management is responsible for the operational oversight of company-wide cybersecurity strategy, policy, and standards across relevant departments to assess and help prepare us to address cybersecurity risks.

Insider Trading Arrangements	12 Months Ended
Insider Trading Arrangements	Dec. 31, 2025
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Modified	false
Non-Rule 10b5-1 Arrangement Modified	false

SCHEDULE OF ASSUMPTIONS USED TO DETERMINE FAIR VALUE OF OPTIONS GRANTED (Details)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate, minimum	4.22%	3.72%
Risk-free interest rate, maximum	4.55%	4.50%
Expected volatility, minimum	101.70%	101.70%
Expected volatility, maximum	123.22%	115.80%
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected life (in years)	9 years	7 years 6 months
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected life (in years)	10 years	10 years

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

OTHER ACCRUED LIABILITIES

12 Months Ended

Dec. 31, 2025

Payables and Accruals [Abstract]

OTHER ACCRUED LIABILITIES

5. OTHER ACCRUED LIABILITIES

Other accrued liabilities at December 31, 2025 and 2024 include the following:

SCHEDULE OF OTHER ACCRUED LIABILITIES

	2025		2024
	December 31,
	2025		2024
Amounts due to contract research organizations and other contractual agreements	$	1,001,210	$	1,048,036
Accrued payroll and related benefits		1,611,936		1,945,111
Professional fees, franchise taxes and other		211,500		40,600
Total	$	2,824,646	$	3,033,747

SEGMENT PERFORMANCE MEASURES AND EXPENSES (Tables)

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES AND CONSOLIDATED NET LOSS

The following table provides a summary of the significant expense categories and consolidated net loss details provided to the CODM (in thousands):

	2025			2024
	For the year ended December 31,
	(In thousands)						Change Increase (Decrease)
	2025			2024
Operating Expenses:
Clinical Research
OVATION 2 and MRD Trials	$	402		$	1,386		$	(984	)	(71.1	)%
OVATION 3 Trial		1,313			-			1,313		-	%
PlaCCine Vaccine Phase 1 Trial		10			1,420			(1,410	)	(99.3	)%
Other Clinical and Regulatory		1,910			2,434			(524	)	(21.5	)%
Subtotal		3,635			5,240			(1,605	)	(30.6	)%
Non-Clinical R&D and CMC
OVATION Program		2,999			1,819			1,180		64.9	%
PlaCCine Vaccine Program		-			2,554			(2,554	)	(100.0	)%
Manufacturing (CMC)		1,147			2,026			(879	)	(43.4	)%
Subtotal		4,146			6,399			(2,253	)	(35.2	)%

Research and development expenses		7,781			11,639			(3,858	)	(33.1	)%
General and administrative expenses		6,870			7,493			(623	)	(8.3	)%
Total operating expenses		14,651			19,132			(4,493	)	(23.4	)%
Loss from operations	$	(14,651	)	$	(19,132	)	$	4,493		(23.4	)%

WARRANTS (Tables)

12 Months Ended

Dec. 31, 2025

Warrants

SUMMARY OF WARRANT ACTIVITY

Following is a summary of all warrant activity for the two years ended December 31, 2025:

SUMMARY OF WARRANT ACTIVITY

Warrants	Number of Warrants Issued			Weighted Average Exercise Price
Warrants outstanding at January 1, 2024		12,272		$	246.00

Warrants issued during 2024		383,333			26.09
Warrants expired during 2024		(381	)	$	154.57
Warrants outstanding and exercisable at December 31, 2024		395,224		$	32.74
Warrants issued during 2025		5,024,066		$	2.68
Warrants exercised during 2025 – cashless exchange		(223,946	)	$	-
Warrants exercised during 2025		(671,732	)	$	5.16
Warrants expired during 2025		(10,137	)	$	242.61
Warrants outstanding and exercisable at December 31, 2025		4,513,475		$	5.04

Weighted average remaining contractual terms (years)		4.2	{a}

{a}

Amount excludes ~1.6 million prefunded warrants from the December 2025 financing which have no expiration date.

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)											12 Months Ended
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	Mar. 31, 2026	Dec. 29, 2025	Jul. 25, 2025	Jul. 22, 2025	Jun. 02, 2025	May 23, 2025	May 12, 2025	Sep. 03, 2024	Jul. 30, 2024	May 15, 2024	Dec. 31, 2025	Dec. 31, 2024	Jul. 28, 2025	Jul. 11, 2025
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued during period, value, new issues				$ 79,075,969	$ 75,000,000.0					$ 75,000,000	$ 13,628,070	$ 9,060,438
Stock issued, shares				2,121,895	2,100,291
Share price			$ 1.00		$ 37.65
Reverse stock split			15-for-1 reverse stock split
Common stock, shares issued			15								3,419,652	966,714
Common stock, shares outstanding			15								3,419,650	966,712
Reverse stock split shares			31,828,447
Number of authorized shares of common stock											350,000,000	112,500,000
Stock dividend percentage													15.00%
Dividend per share													$ 0.15
Proceeds from issuance of common stock				$ 1,815,267				$ 5,500,000			$ 13,628,070	$ 9,060,438
Prospectus supplement covers aggregate shares				8,184,733
Remaining amount				3,684,733
Additional prospectus supplement amount				4,500,000
Common stock par value											$ 0.01	$ 0.01
July 2024 Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock outstanding percentage							19.98%
May 2025 Warrant Exchange [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued, shares							333,334
Common stock par value							$ 0.01
Warrants outstanding							194,734
Sales Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Proceeds from issuance of common stock				5,500,000
At the Market Offering Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued during period, value, new issues				$ 4,500,000						$ 5,500,000
Share price				$ 0.01
Number of shares sold											744,646	5,920
Proceeds from sale of stock											$ 4,530,663	$ 99,506
Securities Purchase Agreement [Member] \| July 2024 Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued, shares									333,334
Share price									$ 30.00
Proceeds from issuance of common stock									$ 10,000,000.0
Securities Purchase Agreement [Member] \| May 2025 Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued, shares						185,186
Proceeds from issuance of common stock						$ 3,300,000
Securities Purchase Agreement [Member] \| December Two Thousand Twenty Five Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued, shares		330,000
Proceeds from issuance of common stock						$ 7,000,000.0
Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Options outstanding			$ 1,900,000
Stock awards reduced			12,700,000										$ 800,000
Number of authorized shares of common stock														350,000,000
Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Options outstanding			100,000
Stock awards reduced			$ 800,000										$ 1,000,000.0
Number of authorized shares of common stock														112,500,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued during period, value, new issues											$ 15,562	$ 3,393
Stock issued, shares											1,556,129	339,251
Reverse stock split shares			2,121,942								70,448
Warrant [Member] \| Securities Purchase Agreement [Member] \| July 2024 Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued, shares									333,334
Share price									$ 30.00
Warrant [Member] \| Securities Purchase Agreement [Member] \| May 2025 Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued, shares						962,964
Share price						$ 6.75
Pre Funded [Member] \| Securities Purchase Agreement [Member] \| May 2025 Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued, shares						296,297
Share price						$ 0.0001
Placement Agents Warrant [Member] \| Securities Purchase Agreement [Member] \| May 2025 Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued, shares						24,075
Share price						$ 8.44
Pre Funded Warrant Shares [Member] \| Securities Purchase Agreement [Member] \| December Two Thousand Twenty Five Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued, shares		1,609,114									1,600,000
Pre Funded Warrant [Member] \| Securities Purchase Agreement [Member] \| December Two Thousand Twenty Five Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued, shares		1,939,114
Prefunded Warrant And Shares [Member] \| Securities Purchase Agreement [Member] \| December Two Thousand Twenty Five Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share price		$ 3.61
Prefunded Warrant And Warrants [Member] \| Securities Purchase Agreement [Member] \| December Two Thousand Twenty Five Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share price		3.6099
PreFunded Warrants [Member] \| Securities Purchase Agreement [Member] \| December Two Thousand Twenty Five Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant price		$ 0.0001
PreFunded Warrants [Member] \| Securities Purchase Agreement [Member] \| December Two Thousand Twenty Five Offering [Member] \| Company With Affiliates [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Equity ownership percentage		9.99%
Warrants [Member] \| Securities Purchase Agreement [Member] \| December Two Thousand Twenty Five Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share price		$ 3.482
Warrants [Member] \| Securities Purchase Agreement [Member] \| December Two Thousand Twenty Five Offering [Member] \| Company With Affiliates [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Equity ownership percentage		4.99%
PreFunded Warrants And Warrants [Member] \| Securities Purchase Agreement [Member] \| December Two Thousand Twenty Five Offering [Member] \| Company With Affiliates [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Equity ownership percentage		19.99%
Subsequent Event [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued during period, value, new issues	$ 75,000,000.0

SEGMENT PERFORMANCE MEASURES AND EXPENSES (Details Narrative)	12 Months Ended
	Dec. 31, 2025 Segment
Segment Reporting [Abstract]
Number of operating segment	1
Number of reportable segment	1

SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details) - USD ($)

12 Months Ended

Dec. 31, 2025

Dec. 31, 2024

Income Tax Disclosure [Abstract]

Net loss

$ (14,495,028)

$ (18,620,242)

Net Loss Tax Effected

$ (3,043,956)

Net Loss, percent

21.00%

Change in Valuation Allowance

$ 1,215,757

Change in valuation allowance and deferred rate change, net, percent

(8.39%)

(9.01%)

Federal statutory rate, percent

21.00%

State taxes, net of federal tax benefit, percent

^[1]

8.40%

Permanent differences, percent

(2.74%)

True-Up, percent

(0.07%)

Rate Change, percent

0.57%

Deferred vs statutory rate, percent

(0.75%)

Equity based comp

$ 26,743

Equity based comp, percent

(0.18%)

Expired NOL's Federal

$ 1,703,110

Expiration of NOLs, percent

(11.75%)

(17.51%)

Other Adjustments - Equity based comp adjustment

$ 98,346

Other Adjustments - Equity based comp adjustment, percent

(0.68%)

0.11%

Total

Total income tax provision (benefit), percent

[1]	State taxes in New Jersey made up the majority (greater than 50%) of the tax effects in this category for 2024-2025.

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) (Parenthetical)	Dec. 31, 2025
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years
Machinery and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	5 years
Machinery and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years
Furniture and Fixtures [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Furniture and Fixtures [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	5 years
Leasehold Improvements [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	5 years
Leasehold Improvements [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Property, Plant and Equipment [Line Items]
Property and equipment gross	$ 1,805,877	$ 1,737,567
Less accumulated depreciation and amortization	(1,275,941)	(1,196,295)
Total	529,936	541,272
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	938,377	951,192
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	167,351	167,351
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	$ 700,149	$ 619,024

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2025

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Description of Business

Imunon, Inc. (“Imunon” , the “Company”, “we”, “our”, or “us”) is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms with the aim to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of vaccines in infectious diseases.

The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase II clinical trial (OVATION 2) and is currently conducting a Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions.

Basis of Presentation

The accompanying consolidated financial statements (“Financial Statements”) of Imunon have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company and its subsidiary, CLSN Laboratories, Inc.

Accounting Standards Update

In December 2023, the financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-09, Income Taxes (Topic 740)—Improvements to Income Tax Disclosures. The standard requires enhanced annual disclosures, including: (i) disaggregated information in the rate reconciliation, (ii) disaggregation of income (loss) from continuing operations before income tax expense (benefit) between domestic and foreign, (iii) disaggregation of income tax expense (benefit) from continuing operations by federal, state, and foreign, and (iv) disaggregated disclosure of income taxes paid by jurisdiction. The Company adopted ASU 2023-09 on January 1, 2025 prospectively. The adoption of ASU 2023-09 resulted in expanded income tax disclosures in this note.

In November 2024, the FASB issued ASU No. 2024-03, “Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses” (“ASU 2024-03”). ASU 2024-03 will require more detailed information about the types of expenses in commonly presented income statement captions such as “Cost of sales” and “Selling, general and administrative expenses”. The new guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact, if any, this change will have on the Company’s disclosures.

In December 2025, the FASB issued ASU 2025-11, “Narrow Scope Improvements” (“ASU 2025-11”) which is intended to improve the navigability of the guidance in Interim Reporting (Topic 270) and clarify when it applies. Under the amendments, an entity is subject to ASC 270 if it provides “interim financial statements and notes in accordance with GAAP.” ASU 2025-11 also addresses the form and content of such financial statements, adds lists to ASC 270 of the interim disclosures required by all other codification topics, and establishes a principle under which an entity must “disclose events since the end of the last annual reporting period that have a material impact on the entity.” As the FASB stated in the proposed guidance and reiterates in 2025-11, the amendments are not intended to “change the fundamental nature of interim reporting or expand or reduce current interim disclosure requirements. ASU 2025-11 is effective for interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company does not believe ASU 2025-11 will have a material effect on its consolidated financial statements.

Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that the Company believes have a material impact, or potential material impact, to its consolidated financial statements.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of expenses during the reporting period. Actual results could differ significantly from those estimates. The most significant estimates relate to the accrual of research and development expenses and the valuation of stock-based compensation.

Revenue Recognition

The Company did not generate any revenue in 2025 or 2024, and there were no accounts receivable as of December 31, 2025 and 2024.

Cash and Cash Equivalents

Cash and cash equivalents include cash on hand and investments purchased with an original maturity of three months or less. A portion of these funds is not covered by Federal Deposit Insurance Corporation.

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash held by various financial institutions either above the federally insured limit or not covered by federal deposit insurance. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash to the extent recorded in the balance sheet. The Company has not experienced any losses on its deposits. Losses incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flow.

Fair Value of Financial Instruments

The carrying values of financial instruments approximate their respective fair values. Management believes that the carrying amounts of the Company’s financial instruments, including cash and cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments.

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is provided over the estimated useful lives of the related assets, ranging from three3 to seven years, using the straight-line method. Amortization is recognized over the lesser of the life of the asset or the lease term. Major renewals and improvements are capitalized at cost and ordinary repairs and maintenance are charged against operating expenses as incurred. Depreciation expense was approximately $292,000 and $240,000 for the years ended December 31, 2025 and 2024, respectively.

The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An asset is considered impaired if its carrying amount exceeds the future net undiscounted cash flows that the asset is expected to generate. If such asset is considered to be impaired, the impairment recognized is the amount by which the carrying amount of the asset, if any, exceeds its fair value determined using a discounted cash flow model. There was no impairment of property or equipment during 2025 or 2024.

Advances and Deposits on Clinical Programs and Other Current Assets

Supplies are consumable items kept on hand to support the Company’s research and development and manufacturing operations which includes prepaid expense, raw materials, clinical supplies, and consumable items for clinical trials with alternate uses that are capitalized. Supplies are recorded at cost and are charged to expense as they are used in operations. The Company regularly reviews the quality and utilization of supplies to determine if future use of these supplies is probable. Due to the generic use of these supplies, they can be used in multiple projects other than those currently being studied.

Deposits

Deposits include a real property security deposit which is contractually required and of a long-term nature.

Comprehensive Income (Loss)

ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive income (loss) and its components in the Company’s consolidated financial statements. The objective of ASC 220 is to report a measure of comprehensive income (loss) of all changes in equity of an enterprise that result from transactions and other economic events in a period other than transactions with owners. Comprehensive gains (losses) may result from changes in unrealized gains and losses from investment in debt securities. The Company did not have any comprehensive income or loss during 2025. The Company had net realized gains and losses of $60,796 resulting in a comprehensive loss during 2024. No accumulated other comprehensive income or loss existed on December 31, 2025 or 2024.

Research and Development

Research and development costs are expensed as incurred. Supplies are consumable, recorded at cost and are charged to expense as they are used in operations. Equipment and facilities acquired for research and development activities that have alternative future uses are capitalized and charged to expense over their estimated useful lives.

Net Loss per Share of Common Stock

Basic and diluted net loss per common share was computed by dividing net loss for the year by the weighted average number of shares of common stock outstanding, both basic and diluted, during each period. The impact of common stock equivalents has been excluded from the computation of diluted weighted average common shares outstanding in periods where there is a net loss, as their effect is anti-dilutive.

As more fully described in Note 7 of these consolidated financial statements, the Company declared a 15% stock dividend that was distributed on August 21, 2025 to stockholders of record as of August 7, 2025. In accordance with ASC 260, basic and diluted earnings per share amounts and weighted-average shares outstanding have been restated for all periods presented to reflect the effect of this stock dividend. The Company did not pay any dividends during 2024.

As more fully described in Note 7 of these consolidated financial statements, on December 31, 2025, the Company completed the sale of a security offering which included prefunded warrants to purchase up to 1,609,114 shares of the Company’s common stock for $0.01 per share. In accordance with ASC 260-10-45-13, these pre-funded warrants, sometimes referred to as penny stock warrants due to their low exercise price ($0.0001/share), are considered outstanding shares for purpose of calculating earnings per share.

For the years ended December 31, 2025 and 2024, the total number of shares of common stock issuable upon exercise of warrants and equity awards was 2,923,056 and 456,042, respectively. For the years ended December 31, 2025 and 2024, diluted loss per common share is the same as basic loss per common share as all options and all other warrants that were convertible into shares of the Company’s common stock were excluded from the calculation of diluted earnings attributable to common stockholders per common share as their effect would be anti-dilutive.

Income Taxes

Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in results of operations in the period that the tax rate change occurs. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. In accordance with ASC 740, Income Taxes, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position taken would be sustained in a tax examination, presuming that a tax examination will occur. The Company recognizes interest and/or penalties related to income tax matters in the income tax expense category.

Stock-Based Compensation

The Company accounts for all share-based payment awards granted to employees and non-employees as stock-based compensation expense at grant date fair value. The Company’s share-based payments include stock options and grants of common stock, including common stock subject to vesting. The measurement date for employee awards is the date of grant, and stock-based compensation costs are recognized as expense over the employees’ requisite service period, which is the vesting period, on a straight-line basis. Prior to the adoption of ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting on January 1, 2020, the measurement date for non-employee awards was generally the date the services were completed, resulting in financial reporting period adjustments to stock-based compensation during the vesting terms for changes in the fair value of the awards. Since the adoption of ASU 2018-07, the measurement date for non-employee awards is the date of grant without changes in the fair value of the award. There was no material impact as a result of adopting this new standard. Stock-based compensation costs for non-employees are recognized as expense over the vesting period on a straight-line basis. Stock-based compensation expense is classified in the accompanying consolidated statements of operations based on the function to which the related services are provided. Forfeitures are recorded as they occur.

The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company utilizes its historical data regarding the volatility of its own traded stock price. The expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.

Warrant Accounting

We account for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrants’ specific terms and applicable authoritative guidance in ASC 480, “Distinguishing Liabilities from Equity” (“ASC 480”), and ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to our own ordinary shares and whether warrant holders could potentially require “net cash settlement” in a circumstance outside of our control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end-date while the warrants are outstanding.

For issued or modified warrants that meet all the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of warrants classified as liabilities are recognized as a non-cash gain or loss on our consolidate statements of operations.

As the warrants issued upon our financings in 2025 and 2024 meet the criteria for equity classification under ASC 815, those warrants were classified as equity as of December 31, 2025 and 2024.

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the FASB and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued accounting pronouncements will not have a material impact on the Company’s consolidated financial position, results of operations, and cash flows, or do not apply to its operations. See disclosure above relating to ASU No. 2023-09 and ASU 2024-03.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)		12 Months Ended
	Aug. 07, 2025	Dec. 31, 2025	Dec. 31, 2024	Jul. 25, 2025	Jun. 02, 2025
Property, Plant and Equipment [Line Items]
Accounts receivable		$ 0	$ 0
Depreciation expense		292,000	240,000
Impairment of property or equipment		0	0
Realized gains and losses			60,796
accumulated other comprehensive income or loss		$ 0	$ 0
Stock dividend percentage	15.00%
Share price				$ 1.00	$ 37.65
Number of shares of common stock issuable upon exercise of warrants and equity awards		2,923,056	456,042
PreFunded Warrants [Member]
Property, Plant and Equipment [Line Items]
Warrants outstanding		1,609,114
Share price		$ 0.01
Warrant exercise price		$ 0.0001
Minimum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life		3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life		7 years

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 75,150,030	$ 66,141,490
Section 174		6,482,099
Other deferred tax assets, net	1,628,991	2,010,744
Subtotal	76,779,021	74,634,333
Valuation allowance	(76,779,021)	(74,634,333)
Total deferred tax asset

SUMMARY OF NON-VESTED RESTRICTED STOCK AWARDS (Details) - $ / shares	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Number Outstanding, Non-vested stock awards, Outstanding, Beginning balance	2,647	2,140
Weighted Average Grant Date Fair Value, Non-vested stock awards, Outstanding, Beginning balance	$ 14.85	$ 18.45
Number Outstanding, Non-vested stock awards, Granted		2,647
Weighted Average Grant Date Fair Value, Non-vested stock awards, Granted		$ 14.85
Number Outstanding, Non-vested stock awards, Vested and issued	(2,647)	(807)
Weighted Average Grant Date Fair Value, Non-vested stock awards, Vested and issued	$ 14.85	$ 27.60
Number Outstanding, Non-vested stock awards, Forfeited		(1,333)
Weighted Average Grant Date Fair Value, Non-vested stock awards, Forfeited		$ 13.20
Number Outstanding, Non-vested stock awards, Outstanding, Beginning balance		2,647
Weighted Average Grant Date Fair Value, Non-vested stock awards, Outstanding, Beginning balance		$ 14.85

STOCK-BASED COMPENSATION (Tables)

12 Months Ended

Dec. 31, 2025

Share-Based Payment Arrangement [Abstract]

SCHEDULE OF 2018 ASHM PLAN AMENDMENTS

Shareholder Approval Event	2018 Plan (as adopted and amended)	Number of awards approved		Cumulative Awards Approved
2018 ASHM	2018 Plan Adoption		12,000		12,000
2019 ASHM	Amendment #1		5,333		17,333
2020 ASHM	Amendment #2		11,111		28,444
2021 ASHM	Amendment #3		34,222		62,666
2023 ASHM	Amendment #4		68,666		131,332
2025 ASHM	Amendment #5		133,333		264,665

SUMMARY OF STOCK OPTIONS

A summary of stock option awards outstanding as of December 31, 2025 and changes during the two-year period ending December 31, 2025 is presented below.

SUMMARY OF STOCK OPTIONS

Stock Options	Number Outstanding			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Outstanding at January 1, 2024		70,899		$	39.15
Options granted		70,122		$	16.80
Options canceled or expired		(31,296	)	$	23.70
Outstanding at December 31, 2024		109,725		$	29.31
Options granted		35,943		$	11.45
Options canceled or expired		(126,973	)	$	26.26
Outstanding at December 31, 2025		18,695		$	15.68		9.0	$	-

Exercisable at December 31, 2025		11,011		$	19.65		8.7	$	-

SUMMARY OF NON-VESTED RESTRICTED STOCK AWARDS

A summary of the status of the Company’s non-vested restricted stock awards as of December 31, 2025 and changes during the two-year period ended December 31, 2025, is presented below.

Restricted Stock	Number Outstanding			Weighted Average Grant Date Fair Value
Non-vested stock awards outstanding at January 1, 2024		2,140		$	18.45
Granted		2,647		$	14.85
Vested and issued		(807	)	$	27.60
Forfeited		(1,333	)	$	13.20
Non-vested stock awards outstanding at December 31, 2024		2,647		$	14.85
Vested and issued		(2,647	)	$	14.85
Non-vested stock awards outstanding at December 31, 2025		-		$	-

SUMMARY OF STOCK OPTIONS OUTSTANDING

A summary of stock options outstanding at December 31, 2025 by price range is as follows:

SUMMARY OF STOCK OPTIONS OUTSTANDING

			Options Outstanding				Options Exercisable
Range of Exercise Prices	Number		Weighted Average Remaining Contractual Term (in years)		Weighted Average Exercise Price		Number		Weighted Average Remaining Contractual Term (in years)		Weighted Average Exercise Price

$9.20		14,485		9.6	$	9.20		7,252		9.6	$	9.20
$9.21 to $19.80		2,404		8.3	$	15.93		1,953		8.3	$	16.09
Above $19.80		1,806		5.5	$	67.28		1,806		5.5	$	67.28
		18,695						11,011

SCHEDULE OF ASSUMPTIONS USED TO DETERMINE FAIR VALUE OF OPTIONS GRANTED

The fair values of stock options granted were estimated at the date of grant using the Black-Scholes option pricing model. The Black-Scholes model was originally developed for use in estimating the fair value of traded options, which have different characteristics from Imunon’s stock options. The model is also sensitive to changes in assumptions, which can materially affect the fair value estimate. The Company used the following assumptions for determining the fair value of options granted under the Black-Scholes option pricing model:

	Year Ended December 31,
	2025			2024
Risk-free interest rate		4.22% to 4.55	%		3.72% to 4.50	%
Expected volatility		101.7% to 123.22	%		101.7% to 115.8	%
Expected life (in years)		9.0 to 10.0			7.5 to 10
Expected dividend yield		0.0	%		0.0	%

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Dec. 31, 2025
Accounting Policies [Abstract]
Description of Business	Description of Business Imunon, Inc. (“Imunon” , the “Company”, “we”, “our”, or “us”) is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms with the aim to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of vaccines in infectious diseases. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase II clinical trial (OVATION 2) and is currently conducting a Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions.
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements (“Financial Statements”) of Imunon have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company and its subsidiary, CLSN Laboratories, Inc.
Accounting Standards Update	Accounting Standards Update In December 2023, the financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-09, Income Taxes (Topic 740)—Improvements to Income Tax Disclosures. The standard requires enhanced annual disclosures, including: (i) disaggregated information in the rate reconciliation, (ii) disaggregation of income (loss) from continuing operations before income tax expense (benefit) between domestic and foreign, (iii) disaggregation of income tax expense (benefit) from continuing operations by federal, state, and foreign, and (iv) disaggregated disclosure of income taxes paid by jurisdiction. The Company adopted ASU 2023-09 on January 1, 2025 prospectively. The adoption of ASU 2023-09 resulted in expanded income tax disclosures in this note. In November 2024, the FASB issued ASU No. 2024-03, “Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses” (“ASU 2024-03”). ASU 2024-03 will require more detailed information about the types of expenses in commonly presented income statement captions such as “Cost of sales” and “Selling, general and administrative expenses”. The new guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact, if any, this change will have on the Company’s disclosures. In December 2025, the FASB issued ASU 2025-11, “Narrow Scope Improvements” (“ASU 2025-11”) which is intended to improve the navigability of the guidance in Interim Reporting (Topic 270) and clarify when it applies. Under the amendments, an entity is subject to ASC 270 if it provides “interim financial statements and notes in accordance with GAAP.” ASU 2025-11 also addresses the form and content of such financial statements, adds lists to ASC 270 of the interim disclosures required by all other codification topics, and establishes a principle under which an entity must “disclose events since the end of the last annual reporting period that have a material impact on the entity.” As the FASB stated in the proposed guidance and reiterates in 2025-11, the amendments are not intended to “change the fundamental nature of interim reporting or expand or reduce current interim disclosure requirements. ASU 2025-11 is effective for interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company does not believe ASU 2025-11 will have a material effect on its consolidated financial statements. Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that the Company believes have a material impact, or potential material impact, to its consolidated financial statements.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of expenses during the reporting period. Actual results could differ significantly from those estimates. The most significant estimates relate to the accrual of research and development expenses and the valuation of stock-based compensation.
Revenue Recognition	Revenue Recognition The Company did not generate any revenue in 2025 or 2024, and there were no accounts receivable as of December 31, 2025 and 2024.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash on hand and investments purchased with an original maturity of three months or less. A portion of these funds is not covered by Federal Deposit Insurance Corporation. Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash held by various financial institutions either above the federally insured limit or not covered by federal deposit insurance. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash to the extent recorded in the balance sheet. The Company has not experienced any losses on its deposits. Losses incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flow.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying values of financial instruments approximate their respective fair values. Management believes that the carrying amounts of the Company’s financial instruments, including cash and cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments.
Property and Equipment	Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is provided over the estimated useful lives of the related assets, ranging from three3 to seven years, using the straight-line method. Amortization is recognized over the lesser of the life of the asset or the lease term. Major renewals and improvements are capitalized at cost and ordinary repairs and maintenance are charged against operating expenses as incurred. Depreciation expense was approximately $292,000 and $240,000 for the years ended December 31, 2025 and 2024, respectively. The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An asset is considered impaired if its carrying amount exceeds the future net undiscounted cash flows that the asset is expected to generate. If such asset is considered to be impaired, the impairment recognized is the amount by which the carrying amount of the asset, if any, exceeds its fair value determined using a discounted cash flow model. There was no impairment of property or equipment during 2025 or 2024.
Advances and Deposits on Clinical Programs and Other Current Assets	Advances and Deposits on Clinical Programs and Other Current Assets Supplies are consumable items kept on hand to support the Company’s research and development and manufacturing operations which includes prepaid expense, raw materials, clinical supplies, and consumable items for clinical trials with alternate uses that are capitalized. Supplies are recorded at cost and are charged to expense as they are used in operations. The Company regularly reviews the quality and utilization of supplies to determine if future use of these supplies is probable. Due to the generic use of these supplies, they can be used in multiple projects other than those currently being studied.
Deposits	Deposits Deposits include a real property security deposit which is contractually required and of a long-term nature.
Comprehensive Income (Loss)	Comprehensive Income (Loss) ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive income (loss) and its components in the Company’s consolidated financial statements. The objective of ASC 220 is to report a measure of comprehensive income (loss) of all changes in equity of an enterprise that result from transactions and other economic events in a period other than transactions with owners. Comprehensive gains (losses) may result from changes in unrealized gains and losses from investment in debt securities. The Company did not have any comprehensive income or loss during 2025. The Company had net realized gains and losses of $60,796 resulting in a comprehensive loss during 2024. No accumulated other comprehensive income or loss existed on December 31, 2025 or 2024.
Research and Development	Research and Development Research and development costs are expensed as incurred. Supplies are consumable, recorded at cost and are charged to expense as they are used in operations. Equipment and facilities acquired for research and development activities that have alternative future uses are capitalized and charged to expense over their estimated useful lives.
Net Loss per Share of Common Stock	Net Loss per Share of Common Stock Basic and diluted net loss per common share was computed by dividing net loss for the year by the weighted average number of shares of common stock outstanding, both basic and diluted, during each period. The impact of common stock equivalents has been excluded from the computation of diluted weighted average common shares outstanding in periods where there is a net loss, as their effect is anti-dilutive. As more fully described in Note 7 of these consolidated financial statements, the Company declared a 15% stock dividend that was distributed on August 21, 2025 to stockholders of record as of August 7, 2025. In accordance with ASC 260, basic and diluted earnings per share amounts and weighted-average shares outstanding have been restated for all periods presented to reflect the effect of this stock dividend. The Company did not pay any dividends during 2024. As more fully described in Note 7 of these consolidated financial statements, on December 31, 2025, the Company completed the sale of a security offering which included prefunded warrants to purchase up to 1,609,114 shares of the Company’s common stock for $0.01 per share. In accordance with ASC 260-10-45-13, these pre-funded warrants, sometimes referred to as penny stock warrants due to their low exercise price ($0.0001/share), are considered outstanding shares for purpose of calculating earnings per share. For the years ended December 31, 2025 and 2024, the total number of shares of common stock issuable upon exercise of warrants and equity awards was 2,923,056 and 456,042, respectively. For the years ended December 31, 2025 and 2024, diluted loss per common share is the same as basic loss per common share as all options and all other warrants that were convertible into shares of the Company’s common stock were excluded from the calculation of diluted earnings attributable to common stockholders per common share as their effect would be anti-dilutive.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in results of operations in the period that the tax rate change occurs. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. In accordance with ASC 740, Income Taxes, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position taken would be sustained in a tax examination, presuming that a tax examination will occur. The Company recognizes interest and/or penalties related to income tax matters in the income tax expense category.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for all share-based payment awards granted to employees and non-employees as stock-based compensation expense at grant date fair value. The Company’s share-based payments include stock options and grants of common stock, including common stock subject to vesting. The measurement date for employee awards is the date of grant, and stock-based compensation costs are recognized as expense over the employees’ requisite service period, which is the vesting period, on a straight-line basis. Prior to the adoption of ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting on January 1, 2020, the measurement date for non-employee awards was generally the date the services were completed, resulting in financial reporting period adjustments to stock-based compensation during the vesting terms for changes in the fair value of the awards. Since the adoption of ASU 2018-07, the measurement date for non-employee awards is the date of grant without changes in the fair value of the award. There was no material impact as a result of adopting this new standard. Stock-based compensation costs for non-employees are recognized as expense over the vesting period on a straight-line basis. Stock-based compensation expense is classified in the accompanying consolidated statements of operations based on the function to which the related services are provided. Forfeitures are recorded as they occur. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company utilizes its historical data regarding the volatility of its own traded stock price. The expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.
Warrant Accounting	Warrant Accounting We account for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrants’ specific terms and applicable authoritative guidance in ASC 480, “Distinguishing Liabilities from Equity” (“ASC 480”), and ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to our own ordinary shares and whether warrant holders could potentially require “net cash settlement” in a circumstance outside of our control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end-date while the warrants are outstanding. For issued or modified warrants that meet all the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of warrants classified as liabilities are recognized as a non-cash gain or loss on our consolidate statements of operations. As the warrants issued upon our financings in 2025 and 2024 meet the criteria for equity classification under ASC 815, those warrants were classified as equity as of December 31, 2025 and 2024.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued accounting pronouncements will not have a material impact on the Company’s consolidated financial position, results of operations, and cash flows, or do not apply to its operations. See disclosure above relating to ASU No. 2023-09 and ASU 2024-03.

SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Current
Deferred
State and Local
Current
Deferred
Total

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

SUMMARY OF WARRANT ACTIVITY (Details) - $ / shares

12 Months Ended

Dec. 29, 2025

Jul. 22, 2025

Jun. 02, 2025

Dec. 31, 2025

Dec. 31, 2024

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Number of Warrants Issued, Warrants outstanding, Beginning balance

395,224

12,272

Weighted Average Exercise Price, Warrants outstanding, Beginning balance

$ 32.74

$ 246.00

Number of Warrants Issued, Warrants issued

5,024,066

383,333

Weighted Average Exercise Price, Warrants issued

$ 2.68

$ 26.09

Number of Warrants Issued, Warrants expired

(10,137)

(381)

Weighted Average Exercise Price, Warrants expired

$ 242.61

$ 154.57

Number of Warrants exercised, cashless warrants exercised

(223,946)

Weighted Average Exercise Price,cashless warrants exercised

Number of Warrants exercised, Warrants exercised

(671,732)

Weighted Average Exercise Price, Warrants exercised

$ 5.16

Number of Warrants Issued, Warrants outstanding, Beginning balance

4,513,475

395,224

Weighted Average Exercise Price, Warrants outstanding, Beginning balance

$ 5.04

$ 32.74

Weighted average remaining contractual terms (years)

^[1]

4 years 2 months 12 days

Stock issued, shares

2,121,895

2,100,291

Securities Purchase Agreement [Member] | December Two Thousand Twenty Five Offering [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Stock issued, shares

330,000

Securities Purchase Agreement [Member] | December Two Thousand Twenty Five Offering [Member] | Pre Funded Warrant Shares [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Stock issued, shares

1,609,114

1,600,000

[1]	Amount excludes ~1.6 million prefunded warrants from the December 2025 financing which have no expiration date.

STOCK-BASED COMPENSATION

12 Months Ended

Dec. 31, 2025

Share-Based Payment Arrangement [Abstract]

STOCK-BASED COMPENSATION

8. STOCK-BASED COMPENSATION

The Company has long-term compensation plans that permit the granting of equity-based awards in the form of stock options, restricted stock, restricted stock units, stock appreciation rights, other stock awards, and performance awards.

At the 2018 Annual Stockholders Meeting of the Company (“ASHM”) held on May 15, 2018, stockholders approved the Imunon, Inc. 2018 Stock Incentive Plan (the “2018 Plan”). The 2018 Plan, as originally adopted, permitted the granting of 12,000 shares of Imunon common stock as equity awards in the form of incentive stock options, nonqualified stock options, restricted stock, restricted stock units, stock appreciation rights, other stock awards, performance awards, or in any combination of the foregoing.

Stockholders have since approved amendments to the 2018 Plan at the 2019 ASHM held on May 14, 2019, the 2020 ASHM held on June 15, 2020, the 2021 ASHM held on June 10, 2021, the 2023 ASHM held on June 14, 2023, and at the 2025 ASHM held on July 11, 2025. As of December 31, 2025, a total of 264,665 awards have been approved by the Company’s shareholders for issuance under the 2018 Plan, as amended. There are also 339 awards remaining under prior plans. Following is a schedule of the stock awards approved to the 2018 Plan, as amended:

SCHEDULE OF 2018 ASHM PLAN AMENDMENTS

Shareholder Approval Event	2018 Plan (as adopted and amended)	Number of awards approved		Cumulative Awards Approved
2018 ASHM	2018 Plan Adoption		12,000		12,000
2019 ASHM	Amendment #1		5,333		17,333
2020 ASHM	Amendment #2		11,111		28,444
2021 ASHM	Amendment #3		34,222		62,666
2023 ASHM	Amendment #4		68,666		131,332
2025 ASHM	Amendment #5		133,333		264,665

The Company has issued stock awards to employees and directors in the form of stock options and restricted stock. Options are generally granted with strike prices equal to the fair market value of a share of Imunon common stock on the date of grant. Incentive stock options may be granted to purchase shares of common stock at a price not less than 100% of the fair market value of the underlying shares on the date of grant, provided that the exercise price of any incentive stock option granted to an eligible employee owning more than 10% of the outstanding stock of Imunon must be at least 110% of such fair market value on the date of grant. Only officers and key employees may receive incentive stock options.

Option and restricted stock awards vest upon terms determined by the Compensation Committee of the Board of Directors and are subject to accelerated vesting in the event of a change of control or certain terminations of employment. The Company issues new shares to satisfy its obligations from the exercise of options or the grant of restricted stock awards.

During December 31, 2025 and 2024, the Compensation Committee of the Board of Directors approved the grant of inducement stock options (the “Inducement Option Grants”) to purchase a total of 8,703 and 6,667 shares of Imunon common stock at a weighted average exercise price of $12.93 and $16.10, respectively. Each award had a grant date of the date of grant. Each Inducement Option Grant vested over four years, with one-fourth vesting on the one-year anniversary of the employee’s first day of employment with the Company and one-fourth vesting on the second, third and fourth anniversaries thereafter, subject to the new employee’s continued service relationship with the Company on each such date. Each Inducement Option Grant had a ten-year term and was subject to the terms and conditions of the applicable stock option agreement. During 2025, all 15,730 Inducement Option Grants were cancelled.

As of December 31, 2025, there were a total of 265,004 shares of Imunon common stock reserved for issuance under the 2018 Plan, which were comprised of 18,695 shares of Imunon common stock subject to equity awards previously granted under the 2018 Plan and 2007 Plan and 246,309 shares of Imunon common stock available for future issuance under the 2018 Plan. As of December 31, 2024, there are a total of 130,500 shares of Imunon common stock subject to outstanding inducement awards.

Total compensation cost related to stock options and restricted stock awards was approximately $0.1 million and $0.5 million during 2025 and 2024, respectively. Of these amounts, $32,000 and $0.3 million were charged to research and development expenses during 2025 and 2024, respectively, and $0.1 million and $0.2 million were charged to general and administrative expenses during 2025 and 2024, respectively.

A summary of stock option awards outstanding as of December 31, 2025 and changes during the two-year period ending December 31, 2025 is presented below.

SUMMARY OF STOCK OPTIONS

Stock Options	Number Outstanding			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Outstanding at January 1, 2024		70,899		$	39.15
Options granted		70,122		$	16.80
Options canceled or expired		(31,296	)	$	23.70
Outstanding at December 31, 2024		109,725		$	29.31
Options granted		35,943		$	11.45
Options canceled or expired		(126,973	)	$	26.26
Outstanding at December 31, 2025		18,695		$	15.68		9.0	$	-

Exercisable at December 31, 2025		11,011		$	19.65		8.7	$	-

A summary of the status of the Company’s non-vested restricted stock awards as of December 31, 2025 and changes during the two-year period ended December 31, 2025, is presented below.

Restricted Stock	Number Outstanding			Weighted Average Grant Date Fair Value
Non-vested stock awards outstanding at January 1, 2024		2,140		$	18.45
Granted		2,647		$	14.85
Vested and issued		(807	)	$	27.60
Forfeited		(1,333	)	$	13.20
Non-vested stock awards outstanding at December 31, 2024		2,647		$	14.85
Vested and issued		(2,647	)	$	14.85
Non-vested stock awards outstanding at December 31, 2025		-		$	-

A summary of stock options outstanding at December 31, 2025 by price range is as follows:

SUMMARY OF STOCK OPTIONS OUTSTANDING

			Options Outstanding				Options Exercisable
Range of Exercise Prices	Number		Weighted Average Remaining Contractual Term (in years)		Weighted Average Exercise Price		Number		Weighted Average Remaining Contractual Term (in years)		Weighted Average Exercise Price

$9.20		14,485		9.6	$	9.20		7,252		9.6	$	9.20
$9.21 to $19.80		2,404		8.3	$	15.93		1,953		8.3	$	16.09
Above $19.80		1,806		5.5	$	67.28		1,806		5.5	$	67.28
		18,695						11,011

	Year Ended December 31,
	2025			2024
Risk-free interest rate		4.22% to 4.55	%		3.72% to 4.50	%
Expected volatility		101.7% to 123.22	%		101.7% to 115.8	%
Expected life (in years)		9.0 to 10.0			7.5 to 10
Expected dividend yield		0.0	%		0.0	%

Expected volatilities utilized in the model are based on historical volatility of the Company’s stock price. As of December 31, 2025, there was $44,000 of total unrecognized compensation cost related to non-vested stock-based compensation arrangements. That cost is expected to be recognized over a weighted-average period of 1.0 years.

SCHEDULE OF 2018 ASHM PLAN AMENDMENTS (Details) - Equity Stock Awards [Member]	Dec. 31, 2025 shares
Granted Under Two Thousand Eighteen Plan Adoption [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of awards approved	12,000
Common stock, reserved for future issuance	12,000
Granted Under Two Thousand Eighteen Plan Amendment One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of awards approved	5,333
Common stock, reserved for future issuance	17,333
Granted Under Two Thousand Eighteen Plan Amendment Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of awards approved	11,111
Common stock, reserved for future issuance	28,444
Granted Under Two Thousand Eighteen Plan Amendment Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of awards approved	34,222
Common stock, reserved for future issuance	62,666
Granted Under Two Thousand Eighteen Plan Amendment Four [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of awards approved	68,666
Common stock, reserved for future issuance	131,332
Granted Under Two Thousand Eighteen Plan Amendment Five [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of awards approved	133,333
Common stock, reserved for future issuance	264,665

LEASES (Details Narrative)	1 Months Ended			12 Months Ended
LEASES (Details Narrative)	Apr. 30, 2025 USD ($) ft²	Aug. 31, 2023 USD ($) ft²	Jan. 31, 2023 USD ($) ft²	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Jul. 01, 2026 ft²
Lessee, Lease, Description [Line Items]
Incremental borrowing rate				9.98%
Operating lease, cost				$ 521,457	$ 634,848
Operating lease, payments				519,296	626,323
Amortization expense				$ 407,000	$ 478,000
Lawrenceville New Jersey Lease [Member]
Lessee, Lease, Description [Line Items]
Operating lease, term		24 months
Area of land \| ft²	4,359	9,850
Lawrenceville New Jersey Lease [Member] \| Forecast [Member]
Lessee, Lease, Description [Line Items]
Area of land \| ft²						4,011
Lawrenceville New Jersey Lease [Member] \| Minimum [Member]
Lessee, Lease, Description [Line Items]
Payments for rent	$ 10,361	$ 22,983
Lawrenceville New Jersey Lease [Member] \| Maximum [Member]
Lessee, Lease, Description [Line Items]
Payments for rent	$ 10,863	$ 23,394
Huntsville Alabama Lease [Member]
Lessee, Lease, Description [Line Items]
Operating lease, term			60 months
Area of land \| ft²			11,420
Huntsville Alabama Lease [Member] \| Minimum [Member]
Lessee, Lease, Description [Line Items]
Payments for rent			$ 28,550
Huntsville Alabama Lease [Member] \| Maximum [Member]
Lessee, Lease, Description [Line Items]
Payments for rent			$ 30,903

STOCKHOLDERS’ EQUITY

12 Months Ended

Dec. 31, 2025

Equity [Abstract]

STOCKHOLDERS’ EQUITY

7. STOCKHOLDERS’ EQUITY

On May 15, 2024, the Company filed with the U.S. Securities and Exchange Commission (“SEC”) a shelf registration statement on Form S-3 (the “2024 Registration Statement”) for the offer and sale of up to $75 million of its securities. The 2024 Registration Statement was declared effective on May 22, 2024. The 2024 Registration Statement is intended to provide the Company with flexibility to raise capital in the future for general corporate purposes. As noted in the prospectus supplement that the Company filed on July 22, 2025, the aggregate market value of outstanding Common Stock held by non-affiliates was approximately $79,075,969, based on 2,121,895 shares of Common Stock outstanding as of July 22, 2025, of which 2,100,291 shares were held by non-affiliates, and a price of $37.65 per share, which was the last reported sale price of Common Stock on The Nasdaq Stock Market LLC (“Nasdaq”) on June 2, 2025. As a result, the Company’s public float increased above $75.0 million, and the Company was no longer subject to the limitations contained in General Instruction I.B.6 of Form S-3. Upon the filing of this Form 10K on or about March 31, 2026, the Company’s public float will be less than$75.0 million and as a result, the Company will be subject to the limitations contained in General Instruction I.B.6 of Form S-3.

Reverse Stock Split

On July 25, 2025, the Company effected a 15-for-1 reverse stock split of its common stock which was made effective for trading purposes as of 12:01 a.m. ET on July 25, 2025. As of that date, each 15 shares of issued and outstanding common stock and equivalents were consolidated into one share of common stock. All shares have been restated to reflect the effects of the 15-for-1 reverse stock split. In addition, at the market open on July 25, 2025, the Company’s common stock started trading under a new CUSIP number 15117N701 although the Company’s ticker symbol, IMNN, remained unchanged.

The reverse stock split was previously approved by the Company’s stockholders at the 2025 Annual Meeting held on July 11, 2025, and the Company subsequently filed a Certificate of Amendment to its Certificate of Incorporation to affect the stock consolidation. The primary reasons for the reverse stock split and the amendment are:

	●	To provide the Company with the ability to support its anticipated future growth and would provide greater flexibility to consider and respond to future business opportunities and needs as they arise, including equity financings and stock-based acquisitions of new technology and product development candidates. The availability of additional shares of Common Stock would permit the Company to undertake certain of the foregoing actions without delay and expense associated with holding a Special Meeting of Stockholders to obtain stockholder approval each time such an opportunity arises that would require the issuance of shares of Common Stock; and

	●	To continue listing on The NASDAQ Capital Market, which requires that the Company comply with the applicable listing requirements under NASDAQ Marketplace Rules, which requirements include, among others, a minimum bid price of at least $1.00 per share.

Immediately prior to the reverse stock split, the Company had 31,828,447 shares of common stock outstanding which consolidated into 2,121,942 shares of the Company’s common stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares were rounded up to the nearest whole share. The reverse stock split did not impact the total authorized number of shares of common or preferred stock or the par value thereof. The number of outstanding options, stock awards and warrants were adjusted accordingly, with outstanding options and stock awards being reduced from approximately 1.9 million to approximately 0.1 million and outstanding warrants being reduced from approximately 12.7 million to approximately 0.8 million.

Increase to Authorized Shares

At the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of the Company held on July 11, 2025, upon the recommendation of the Company’s board of directors, the Company’s stockholders voted on and approved an amendment to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 112,500,000 shares to 350,000,000 shares, and to make a corresponding change to the number of authorized shares of capital stock. Such amendment became effective on July 11, 2025 upon filing with the Secretary of State of the State of Delaware.

Stock Dividend

On July 28, 2025, the Company announced that the Company’s Board of Directors approved a 15% stock dividend, 0.15 shares of common stock (the “Stock Dividend”) per share of the Company’s issued and outstanding shares of common stock and per each common stock equivalent with dividend rights.

The Board of Directors fixed August 7, 2025 as the record date (the “Record Date”) for the Stock Dividend, and the Stock Dividend was issued on August 21, 2025 to stockholders of record as of the Record Date.

The number of outstanding warrants were adjusted accordingly, with outstanding warrants increasing from approximately 0.8 million to approximately 1.0 million.

At the Market Offering Agreement

On May 15, 2024, the Company amended the At the Market Offering Agreement, dated as of May 25, 2022 (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”) as sales agent. Pursuant to the terms of the amended ATM Agreement, the Company may offer and sell, from time to time, through Wainwright, shares of the Company’s common stock having an aggregate offering price of up to $5,500,000. The Company intends to use the net proceeds from any offering under the amended ATM Agreement for general corporate purposes, including research and development activities, capital expenditures and working capital.

●

On July 30, 2024, the Company notified Wainwright that it was suspending its use of and terminating the “at the market offering” sales agreement prospectus (the “ATM Prospectus”), related to the potential issuance from time to time of the Company’s common stock pursuant to the ATM Agreement, by and between the Company and Wainwright. Notwithstanding the termination of the ATM Prospectus, the ATM Agreement remains in full force and effect.

●

On September 3, 2024, the Company filed a new prospectus supplement to the 2024 Registration Statement with the SEC for an aggregate offering price of up to $5,500,000 related to the potential issuance from time to time of the Company’s common stock pursuant to the ATM Agreement with Wainwright as sales agent.

●

On July 22, 2025, the Company filed a prospectus supplement (the “Prospectus Supplement”) to register an additional $4,500,000 of shares of the Company’s common stock, par value $0.01 per share issuable pursuant to the At the Market Offering Agreement, dated as of May 25, 2022, as amended by Amendment No. 1 to At the Market Offering Agreement, dated as of May 15, 2024 (as amended, the “Sales Agreement”), by and between the Company and H.C. Wainwright & Co., LLC, as sales agent or principal (the “Sales Agent”). The Company previously registered the offer and sale of up to $5,500,000 of shares of Common Stock through the Sales Agent under the Sales Agreement. Prior to the date hereof, the Company has sold an aggregate of $1,815,267 shares of Common Stock through the Sales Agent under the Sales Agreement. Accordingly, the Prospectus Supplement covers an aggregate of $8,184,733 of Shares, consisting of $3,684,733 remaining of the amount originally registered and the additional $4,500,000 increase under the Prospectus Supplement.

During 2025, the Company sold 744,646 and 5,920 shares of common stock under the ATM Agreement for net proceeds of $4,530,663 and $99,506 during 2025 and 2024, respectively.

July 2024 Offering

On July 30, 2024, the Company entered into the July 2024 Purchase Agreement with the Purchasers, pursuant to which the Company issued, in a registered direct offering, an aggregate of 333,334 shares of the Company’s common stock at an offering price of $30.00 per share for gross proceeds of $10.0 million before the deduction of placement agent fees and offering expenses. In a concurrent private placement and also pursuant to the July 2024 Purchase Agreement, the Company issued to the Purchasers the Warrants to purchase an aggregate of 333,334 shares of its common stock at an exercise price of $30.00 per share.

The Warrants became exercisable immediately after issuance for a term of five and one-half years following the date of issuance. The closing of the July 2024 Offering occurred on August 1, 2024.

May 2025 Warrant Exchange

On May 12, 2025, the Company entered into an exchange agreement (the “Agreement”) with the holders (the “Warrant Holders”) of certain warrants of the Company issued on August 1, 2024, which are exercisable for an aggregate of 333,334 shares of the Company’s common stock, par value $0.01 per share. Pursuant to the terms of the Agreement, the Company will issue to the Warrant Holders an aggregate of 194,734 shares of Common Stock (the “Warrant Exchange Shares”), on a one-for-one basis, in exchange for shares issuable under the Warrants (the “Warrant Exchange”), in reliance on an exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended (the “Securities Act”). Pursuant to the Agreement, the Warrant Holders also agreed to waive the Company’s compliance with the provisions of Section 4.12(b) of the Securities Purchase Agreement, dated July 30, 2024, with respect to any Company Variable Rate Transaction (as defined in the Purchase Agreement) for a period of forty-five (45) days from the date of the Agreement and agreed to a lock up period on the Warrant Exchange Shares ending on the opening of trading on May 14, 2025. The Warrant Exchange closed on May 13, 2025. The number of Warrant Exchange Shares that will be issued pursuant to the Agreement will represent 19.98% of the shares of Common Stock outstanding as of the date of the Agreement.

May 2025 Offering

On May 23, 2025, the Company entered into a Securities Purchase Agreement with certain institutional and accredited investors, for the issuance and sale in a private placement of (i) 185,186 shares of the Company’s common stock, (ii) 296,297 of pre-funded warrants at an exercise price of $0.0001 per share and (iii) 962,964 warrants at an exercise price of $6.75 per share for gross proceeds of approximately $3.3 million before the deduction of placement agent fees and offering expenses.

The Prefunded Warrants became exercisable immediately after issuance for a term of two and one-half years following the date of issuance. The Warrants will be exercisable upon receipt of such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market (or any successor entity) from the stockholders of the Company with respect to issuance of all of the Warrants and the shares of Common Stock upon the exercise thereof (“Stockholder Approval,” and such date, the “Stockholder Approval Date”) and have a term of three years. The prefunded warrants were exercised in full on June 16, 2025 and June 18, 2025.

In addition, the Company issued to H.C. Wainwright & Co., LLC warrants (the “Placement Agent Warrants”) to purchase up to an aggregate of 24,075 shares of common stock at an exercise price equal to $8.44 per share. The Placement Agent Warrants have substantially the same terms as the Warrants. The closing of the May 2025 Offering occurred on May 28, 2025. On July 11, 2025, the Company’s stockholders approved the issuance of the Warrants.

December 2025 Offering

On December 29, 2025, the Company entered into a Securities Purchase Agreement (the “December 2025 Purchase Agreement”) with a single healthcare-focused institutional investor (the “Purchaser”) for a registered direct offering (“the December 2025 Offering”) of (i) 330,000 shares of the Company’s common stock, (ii) pre-funded warrants (the “December 2025 Pre-funded Warrants”) in lieu of shares of the Company’s common stock, to the extent the Purchaser so chooses, to purchase up to 1,609,114 shares of the Company’s common stock (the “Pre-funded Warrant Shares”), and (iii) warrants (the “December 2025 Warrants”) to purchase up to 1,939,114 shares of the Company’s common stock. The closing of the December 2025 Offering was completed on December 31, 2025.

The Maxim Group LLC acted as the lead placement agent for the December 2025 Offering. Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as co-placement agent.

The Shares and Warrants were sold at a combined offering price of $3.61 per share of the Company’s common stock and December 2025 Warrant. The December 2025 Pre-funded Warrants and Warrants are being sold at a combined offering price of $3.6099 per December 2025 Pre-funded Warrant and December 2025 Warrant. The December 2025 Pre-funded Warrants have an exercise price of $0.0001, were immediately exercisable and do not have an expiration date. The December 2025 Warrants have an exercise price of $3.482 per share and were immediately exercisable for a term of five years following the date of issuance. The Company cannot effect the exercise of any December 2025 Pre-funded Warrant or December 2025 Warrant, and a holder will not be entitled to exercise any portion of any December 2025 Pre-funded Warrant or December 2025 Warrant, if, upon giving effect to such exercise, the aggregate number of shares of Common Stock beneficially owned by the holder (together with its affiliates) would exceed 9.99% or 4.99%, respectively, of the number of shares of Common Stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the holder’s election upon 61 days’ notice to the Company subject to the terms of such December 2025 Pre-funded Warrants or December 2025 Warrants, provided that such percentage may in no event exceed 19.99%.

The Company received gross proceeds of approximately $7.0 million from the December 2025 Offering, before deducting placement agent fees and other offering expenses payable by the Company. The Company plans to use the proceeds from the Offering for general corporate purposes, including research and development activities, capital expenditures and working capital.

The December 2025 Purchase Agreement contains customary representations and warranties of the Company, on the one hand, and the Purchaser, on the other hand, and customary conditions to closing. As part of the December 2025 Purchase Agreement, subject to certain exceptions, the Company’s officers and directors entered into lock-up agreements, pursuant to which they agreed not to sell or otherwise dispose of any of the Common Stock for a period of 60 days following the date of closing of the December 2025 Offering.

The shares, pre-funded warrants, and warrants issued and sold to the Purchaser under the December 2025 Purchase Agreement were offered and sold by the Company pursuant to an effective registration statement on Form S-3 (Registration No. 333-279425), as previously filed with and declared effective by the SEC and a related prospectus supplement.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Cover - USD ($) $ in Millions	12 Months Ended
Cover - USD ($) $ in Millions	Dec. 31, 2025	Mar. 30, 2026	Jun. 30, 2025
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2025
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2025
Current Fiscal Year End Date	--12-31
Entity File Number	001-15911
Entity Registrant Name	IMUNON, INC.
Entity Central Index Key	0000749647
Entity Tax Identification Number	52-1256615
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	997 LENOX DRIVE
Entity Address, Address Line Two	SUITE 100
Entity Address, City or Town	LAWRENCEVILLE
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08648
City Area Code	(609)
Local Phone Number	896-9100
Title of 12(b) Security	Common Stock, Par Value $0.01 Per Share
Trading Symbol	IMNN
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 21.2
Entity Common Stock, Shares Outstanding		3,922,764
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Auditor Name	WithumSmith+Brown, PC
Auditor Location	East Brunswick, New Jersey
Auditor Firm ID	100

STOCK-BASED COMPENSATION (Details Narrative) - USD ($)	12 Months Ended
STOCK-BASED COMPENSATION (Details Narrative) - USD ($)	Dec. 31, 2025	Dec. 31, 2024	May 15, 2018
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested stock-based compensation arrangements	$ 44,000
Cost recognized over a weighted-average period	1 year
Equity Stock Awards [Member] \| Granted Under Two Thousand Eighteen Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, reserved for future issuance	264,665
Equity Stock Awards [Member] \| Granted Under Two Thousand Eighteen Plan And Prior Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, reserved for future issuance	339
Equity Stock Awards [Member] \| Granted Under 2018 Plan and 2007 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, reserved for future issuance	18,695
Inducement Awards [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, reserved for future issuance		130,500
Stock Options and Restricted Stock Awards [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation	$ 100,000	$ 500,000
Stock Options and Restricted Stock Awards [Member] \| Research and Development Expenses [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation	32,000	300,000
Stock Options and Restricted Stock Awards [Member] \| General and Administrative Expenses [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation	$ 100,000	$ 200,000
2018 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares authorized			12,000
Common stock, reserved for future issuance	265,004
Stock options, strike price description	Options are generally granted with strike prices equal to the fair market value of a share of Imunon common stock on the date of grant. Incentive stock options may be granted to purchase shares of common stock at a price not less than 100% of the fair market value of the underlying shares on the date of grant, provided that the exercise price of any incentive stock option granted to an eligible employee owning more than 10% of the outstanding stock of Imunon must be at least 110% of such fair market value on the date of grant. Only officers and key employees may receive incentive stock options.
Shares available for issuance	246,309
Inducement Option Grants [Member] \| Board of Directors Chairman [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price per share	$ 12.93	$ 16.10
Inducement Option Grants [Member] \| Board of Directors Chairman [Member] \| Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares, Issued	8,703	6,667
Shares, cancelled	15,730

IMUNON EMPLOYEE BENEFIT PLANS

12 Months Ended

Dec. 31, 2025

Retirement Benefits [Abstract]

IMUNON EMPLOYEE BENEFIT PLANS

10. IMUNON EMPLOYEE BENEFIT PLANS

Imunon maintains a defined-contribution plan under Section 401(k) of the Internal Revenue Code. The plan covers substantially all employees over the age of twenty-one. Participating employees may defer a portion of their pretax earnings, up to the Internal Revenue Service annual contribution limit. The Company makes a matching contribution up to a maximum of 3% of an employee’s annual salary. The Company’s total matching contributions for the year ended December 31, 2025 and 2024 were $74,000 and $62,000, respectively.

IMUNON EMPLOYEE BENEFIT PLANS (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Retirement Benefits [Abstract]
Maximum annual contributions per employee, percent	3.00%
Matching contributions of employee	$ 74,000	$ 62,000

SUBSEQUENT EVENTS

12 Months Ended

Dec. 31, 2025

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

14. SUBSEQUENT EVENTS

The Company has evaluated its subsequent events from December 31, 2025, through the date these consolidated financial statements were issued, determining all subsequent events have been disclosed.

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
INCOME TAXES (Details Narrative) - USD ($)	Dec. 31, 2025	Dec. 31, 2024	Jul. 04, 2025	Dec. 31, 2018
Effective Income Tax Rate Reconciliation [Line Items]
Loss before income tax benefit	$ 14,500,000	$ 18,600,000
Income tax reconciliation description		A reconciliation of the provision for income taxes to the amount computed by applying the 21% statutory U.S. federal income tax rate to loss before income taxes
Unrecognized tax benefits	0	$ 0
Payment of interest and penalties	$ 0	$ 0
Income tax examination, description	Under prior law, R&D expenditures were required to be capitalized and amortized over five years for domestic activities and fifteen years for foreign activities. During fiscal year 2025, changes in U.S. federal tax law became effective that permit the immediate deduction of certain domestic R&D expenditures for tax purposes. The Company has applied the provisions of the enacted tax law in accordance with ASC 740, Income Taxes, in the period in which the law became effective.
Capitalized expenses			$ 23,000,000
Domestic Tax Jurisdiction [Member]
Effective Income Tax Rate Reconciliation [Line Items]
Operating loss carryforwards	$ 333,000,000
Operating loss carryforwards expirations	194,000,000
Federal Income Tax [Member] \| No Expiration [Member]
Effective Income Tax Rate Reconciliation [Line Items]
Operating loss carryforwards				$ 139,000,000
State and Local Jurisdiction [Member]
Effective Income Tax Rate Reconciliation [Line Items]
Operating loss carryforwards	$ 78,000,000
Operating loss carryforwards expiration description	expire starting in 2029 through 2043.

SUMMARY OF STOCK OPTIONS (Details) - USD ($)	12 Months Ended
SUMMARY OF STOCK OPTIONS (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number Outstanding, Outstanding, Beginning balance	18,695
Number Outstanding, Exercisable, Ending balance	11,011
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number Outstanding, Outstanding, Beginning balance	109,725	70,899
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 29.31	$ 39.15
Number Outstanding, Options granted	35,943	70,122
Weighted Average Exercise Price, Options granted	$ 11.45	$ 16.80
Number Outstanding, Options canceled or expired	(126,973)	(31,296)
Weighted Average Exercise Price, Options canceled or expired	$ 26.26	$ 23.70
Number Outstanding, Outstanding, Beginning balance	18,695	109,725
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 15.68	$ 29.31
Weighted Average Remaining Contractual Term (years), Outstanding, Ending balance	9 years
Aggregate Intrinsic Value, Outstanding, Ending balance
Number Outstanding, Exercisable, Ending balance	11,011
Weighted Average Exercise Price, Exercisable, Ending balance	$ 19.65
Weighted Average Remaining Contractual Term (years), Exercisable, Ending balance	8 years 8 months 12 days
Aggregate Intrinsic Value, Exercisable, Ending balance

LEASES

12 Months Ended

Dec. 31, 2025

Leases

LEASES

11. LEASES

Lawrenceville, New Jersey Lease - In August 2023, the Company renewed its Lawrenceville office lease for a 24-month agreement for 9,850 square feet with monthly rent payments of approximately $22,983 to $23,394. In April 2025, the Company renewed its Lawrenceville office lease until November 30, 2028 for 4,359 square feet (to be reduced to 4,011 following July 1, 2026) with monthly rent payments of approximately $10,361 to $10,863.

Huntsville, Alabama Lease - In January 2023, the Company renewed its Huntsville facility lease for a 60-month lease agreement for 11,420 square feet with monthly rent payments of approximately $28,550 to $30,903.

The following is a table of the lease payments and maturity of the Company’s operating lease liabilities as of December 31, 2025:

	For the year ending December 31,
2026	$	488,822
2027		498,086
2028		149,896
Subtotal future lease payments		1,136,804
Less imputed interest		(128,039	)
Total lease liabilities	$	1,008,765

Weighted average remaining life		2.4 years

Weighted average discount rate		9.98	%

The discount rate used was the Company’s incremental borrowing rate, which is 9.98%, as the Company could not determine the rate implicit in the lease.

For 2025, operating lease expense was $521,457 and cash paid for operating leases included in operating cash flows was $519,296. For 2024, operating lease expense was $634,848 and cash paid for operating leases included in operating cash flows was $626,323. Amortization expense was approximately $407,000 and $478,000 for the years ended December 31, 2025 and 2024, respectively.

LEASES (Tables)

12 Months Ended

Dec. 31, 2025

Leases

SCHEDULE OF LEASE PAYMENTS AND MATURITY OF OPERATING LEASE LIABILITIES

The following is a table of the lease payments and maturity of the Company’s operating lease liabilities as of December 31, 2025:

	For the year ending December 31,
2026	$	488,822
2027		498,086
2028		149,896
Subtotal future lease payments		1,136,804
Less imputed interest		(128,039	)
Total lease liabilities	$	1,008,765

Weighted average remaining life		2.4 years

Weighted average discount rate		9.98	%

SEGMENT PERFORMANCE MEASURES AND EXPENSES

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

SEGMENT PERFORMANCE MEASURES AND EXPENSES

3. SEGMENT PERFORMANCE MEASURES AND EXPENSES

The Company operates in one segment for the research and development of our product candidates. The Company’s chief operating decision maker (“CODM”) has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company based on consolidated financial information. Consequently, we view the entire organization as one reportable segment and the strategic purpose of all operating activities (including general and administrative expenses) is to support that one segment. As a pre-revenue research and development company, the CODM evaluates company-wide performance and allocates resources based on non-financial research and development milestones achieved, and to a lesser extent, financial measures of performance such as clinical development (research and development expenses) and general and administrative expenses incurred. Our CODM does not generally evaluate our performance using asset or historical cash flow information.

The following table provides a summary of the significant expense categories and consolidated net loss details provided to the CODM (in thousands):

	2025			2024
	For the year ended December 31,
	(In thousands)						Change Increase (Decrease)
	2025			2024
Operating Expenses:
Clinical Research
OVATION 2 and MRD Trials	$	402		$	1,386		$	(984	)	(71.1	)%
OVATION 3 Trial		1,313			-			1,313		-	%
PlaCCine Vaccine Phase 1 Trial		10			1,420			(1,410	)	(99.3	)%
Other Clinical and Regulatory		1,910			2,434			(524	)	(21.5	)%
Subtotal		3,635			5,240			(1,605	)	(30.6	)%
Non-Clinical R&D and CMC
OVATION Program		2,999			1,819			1,180		64.9	%
PlaCCine Vaccine Program		-			2,554			(2,554	)	(100.0	)%
Manufacturing (CMC)		1,147			2,026			(879	)	(43.4	)%
Subtotal		4,146			6,399			(2,253	)	(35.2	)%

Research and development expenses		7,781			11,639			(3,858	)	(33.1	)%
General and administrative expenses		6,870			7,493			(623	)	(8.3	)%
Total operating expenses		14,651			19,132			(4,493	)	(23.4	)%
Loss from operations	$	(14,651	)	$	(19,132	)	$	4,493		(23.4	)%

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

SCHEDULE OF LEASE PAYMENTS AND MATURITY OF OPERATING LEASE LIABILITIES (Details)	Dec. 31, 2025 USD ($)
Leases
2026	$ 488,822
2027	498,086
2028	149,896
Subtotal future lease payments	1,136,804
Less imputed interest	(128,039)
Total lease liabilities	$ 1,008,765
Operating lease, weighted average remaining lease term	2 years 4 months 24 days
Operating lease, weighted average discount rate, percent	9.98%

Consolidated Balance Sheets - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 8,781,059	$ 5,872,767
Advances and deposits on clinical programs and other current assets	1,942,685	2,136,192
Total current assets	10,723,744	8,008,959
Property and equipment (at cost, less accumulated depreciation and amortization)	529,936	541,272
Other assets:
Operating lease right-of-use assets, net	984,436	1,117,133
Deposits and other assets	50,000	50,000
Total other assets	1,034,436	1,167,133
Total assets	12,288,116	9,717,364
Current liabilities:
Accounts payable – trade	1,392,829	1,300,026
Other accrued liabilities	2,824,646	3,033,747
Operating lease liabilities - current portion	406,354	452,358
Total current liabilities	4,623,829	4,786,131
Operating lease liabilities - non-current portion	602,411	686,935
Total liabilities	5,226,240	5,473,066
Commitments and contingencies
Stockholders’ equity:
Preferred Stock - $0.01 par value (100,000 shares authorized, and no shares issued or outstanding at December 31, 2025 and 2024)
Common stock - $0.01 par value (350,000,000 and 112,500,000 shares authorized at December 31, 2025 and 2024, respectively; 3,419,652 and 966,714 shares issued at December 31, 2025 and 2024, respectively, and 3,419,650 and 966,712 shares outstanding at December 31, 2025 and 2024, respectively)	34,197	9,667
Additional paid-in capital	428,410,939	411,122,863
Accumulated deficit	(421,298,072)	(406,803,044)
Total stockholders’ equity before treasury stock	7,147,064	4,329,486
Treasury stock, at cost (2 shares at December 31, 2025 and 2024)	(85,188)	(85,188)
Total stockholders’ equity	7,061,876	4,244,298
Total liabilities and stockholders’ equity	$ 12,288,116	$ 9,717,364

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Operating expenses:
Research and development	$ 7,780,698	$ 11,639,411
General and administrative	6,869,996	7,493,035
Total operating expenses	14,650,694	19,132,446
Loss from operations	(14,650,694)	(19,132,446)
Other income:
Investment income, net	155,666	512,204
Total other income, net	155,666	512,204
Net loss	$ (14,495,028)	$ (18,620,242)
Net loss per common share - basic	$ (6.83)	$ (16.94)
Net loss per common share - diluted	$ (6.83)	$ (16.94)
Weighted average common shares outstanding - basic	2,123,344	1,098,899
Weighted average common shares outstanding - diluted	2,123,344	1,098,899

INCOME TAXES

12 Months Ended

Dec. 31, 2025

Income Tax Disclosure [Abstract]

INCOME TAXES

6. INCOME TAXES

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740)—Improvements to Income Tax Disclosures. The standard requires enhanced annual disclosures, including: (i) disaggregated information in the rate reconciliation, (ii) disaggregation of income (loss) from continuing operations before income tax expense (benefit) between domestic and foreign, (iii) disaggregation of income tax expense (benefit) from continuing operations by federal, state, and foreign, and (iv) disaggregated disclosure of income taxes paid by jurisdiction. The Company adopted ASU 2023-09 on January 1, 2025 prospectively. The adoption of ASU 2023-09 resulted in expanded income tax disclosures in this note.

The Company has incurred substantial net losses since inception and has not generated significant revenue. As a result, the Company has significant net operating loss (“NOL”) carryforwards and other deferred tax assets. The Company maintains a full valuation allowance against its net deferred tax assets because it has concluded that it is more likely than not that these assets will not be realized based on its history of operating losses and expectations of future taxable income.

Loss Before Income Taxes

Loss before income taxes was approximately $14.5 million and $18.6 million for 2025 and 2024, respectively. All these amounts are associated with domestic operations. The components of income tax expense (benefit) for the years ended December 31, 2025 and 2024 consists of the following:

	2025		2024
Federal
Current	$	-	$	-
Deferred		-		-
State and Local		-		-
Current		-		-
Deferred		-		-
Total	$	-	$	-

The reconciliation (ASU 2023-09 tabular format) of the U.S. federal statutory income tax rate to the Company’s effective tax rate for the year ended December 31, 2025 is as follows:

Reconciling Item				Tax Effected			% of Net Loss

Net Loss	$	(14,495,028	)	$	(3,043,956	)		21.00	%

Change in Valuation Allowance					1,215,757			(8.39	)
Federal statutory rate
State taxes, net of federal tax benefit
Permanent differences
True-Up
Rate Change
Deferred vs statutory rate

Nontaxable and Nondeductible items
Equity based comp					26,743			(0.18	)

Expired NOL’s
Federal					1,703,110			(11.75	)

Other Adjustments - Equity based comp adjustment					98,346			(0.68	)
Effective tax rate				$	-0-			- 0-	%

A reconciliation of the provision for income taxes to the amount computed by applying the 21% statutory U.S. federal income tax rate to loss before income taxes for the year prior to the adoption of ASU 2023-09 is as follows:

	2024
Federal statutory rate		21.00	%
State taxes, net of federal tax benefit (1)		8.40
Permanent differences		(2.74	)
True-Up		(0.07	)
Other		0.11
Rate Change		0.57
Deferred vs statutory rate		(0.75	)
Expiration of NOLs		(17.51	)
Change in valuation allowance and deferred rate change, net		(9.01	)
Effective tax rate		-0-	%

(1)

State taxes in New Jersey made up the majority (greater than 50%) of the tax effects in this category for 2024-2025.

The components of the Company’s deferred tax asset as of December 31, 2025 and 2024 are as follows:

	2025			2024
	December 31,
	2025			2024
Net operating loss carryforwards	$	75,150,030		$	66,141,490
Section 174		-			6,482,099
Other deferred tax assets, net		1,628,991			2,010,744
Subtotal		76,779,021			74,634,333
Valuation allowance		(76,779,021	)		(74,634,333	)
Total deferred tax asset	$	-		$	-

The evaluation of the realizability of such deferred tax assets in future periods is made based upon a variety of factors that affect the Company’s ability to generate future taxable income, such as intent and ability to sell assets and historical and projected operating performance. As of December 31, 2025, based on the Company’s history of earnings and its assessment of future earnings, management believes that it is more likely than not future taxable income will not be sufficient to realize the deferred tax assets. Therefore, full valuation allowance has been applied to deferred tax assets.

As of December 31, 2025, the Company had federal net operating loss carry forwards of approximately $333 million. If unused, $194 million will expire starting in 2026 through 2037. The federal NOLs generated for the years ended after 2017 of approximately $139 million can be carried forward indefinitely, subject to certain limitations. As of December 31, 2025, the Company had state net operating loss carryforwards of approximately $78 million, net of net operating losses utilized in prior years, and, if unused, will expire starting in 2029 through 2043.

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. As of December 31, 2025, and 2024, there were no unrecognized tax benefits. The Company recognizes accrued interest and penalties as income tax expense. No amounts were accrued for the payment of interest and penalties at December 31, 2025 and 2024. The Company is currently not aware of any issues under review that could result in significant payments, accruals, or material deviation from its position in the next year.

Sections 382 and 383 of the Internal Revenue Code provide for a limitation on the annual use of NOL and tax credit carryforwards following certain ownership changes that could limit the Company’s ability to utilize these carryforwards. The Company has completed an analysis to determine if such ownership changes have occurred and concluded it was more likely than not that there were changes in ownership. Due to the existence of full valuation allowance, limitations under Section 382 and 383 will not impact the Company’s effective tax rate. Further analyses will be performed prior to recognizing the benefits of any losses or credits in the financial statements.

The Company incurs research and development (“R&D”) expenditures that are subject to the provisions of Section 174 of the Internal Revenue Code. Under prior law, R&D expenditures were required to be capitalized and amortized over five years for domestic activities and fifteen years for foreign activities. During fiscal year 2025, changes in U.S. federal tax law became effective that permit the immediate deduction of certain domestic R&D expenditures for tax purposes. The Company has applied the provisions of the enacted tax law in accordance with ASC 740, Income Taxes, in the period in which the law became effective.

There were no income taxes paid or refunds received for the years ended December 31, 2025 and 2024.

On July 4, 2025, the U.S. federal government enacted the One Big Beautiful Bill Act (OBBBA), which includes significant tax changes, most notably the reinstatement of the immediate expensing of domestic R&D expenditures, effective in fiscal 2025 and 2026. The deductibility of these expenditures reduced our deferred tax assets for periods starting in fiscal 2025. The Company had approximately $23 million of capitalized Section 174 expenses, which Company elected to deduct in 2025 tax year.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

PROPERTY AND EQUIPMENT

12 Months Ended

Dec. 31, 2025

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT

4. PROPERTY AND EQUIPMENT

Property and equipment at December 31, 2025 and 2024 consist of the following:

SCHEDULE OF PROPERTY AND EQUIPMENT

	2025			2024
	December 31,
	2025			2024
Machinery and equipment (5-7 year life)	$	938,377		$	951,192
Furniture and fixtures (3-5 year life)		167,351			167,351
Leasehold improvements (5-7 year life)		700,149			619,024
Property and equipment gross		1,805,877			1,737,567
Less accumulated depreciation and amortization		(1,275,941	)		(1,196,295	)

Total	$	529,936		$	541,272

RELATED PARTY TRANSACTION

12 Months Ended

Dec. 31, 2025

RELATED PARTY TRANSACTION

13. RELATED PARTY TRANSACTION

No material related party transactions.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

+ Details

SCHEDULE OF OTHER ACCRUED LIABILITIES (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Payables and Accruals [Abstract]
Amounts due to contract research organizations and other contractual agreements	$ 1,001,210	$ 1,048,036
Accrued payroll and related benefits	1,611,936	1,945,111
Professional fees, franchise taxes and other	211,500	40,600
Total	$ 2,824,646	$ 3,033,747

SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES AND CONSOLIDATED NET LOSS (Details) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Segment Reporting Information [Line Items]
Research and development expenses	$ 7,780,698	$ 11,639,411
General and administrative expenses	6,869,996	7,493,035
Total operating expenses	14,650,694	19,132,446
Loss from operations	(14,650,694)	(19,132,446)
Operating Segments [Member]
Segment Reporting Information [Line Items]
Change Increase (Decrease), Research and development expenses	(3,858,000)
Research and development expenses	$ 7,781,000	11,639,000
Change Increase (Decrease), Research and development expenses, percentage	(33.10%)
General and administrative expenses	$ 6,870,000	7,493,000
Change Increase (Decrease), General and administrative expenses	$ (623,000)
Change Increase (Decrease), General and administrative expenses, percentage	(8.30%)
Total operating expenses	$ 14,651,000	19,132,000
Change Increase (Decrease), Operating expenses	$ (4,493,000)
Change Increase (Decrease), Operating expenses, percentage	(23.40%)
Loss from operations	$ (14,651,000)	(19,132,000)
Change Increase (Decrease), Loss from operations	$ 4,493,000
Change Increase (Decrease), Loss from operations, percentage	(23.40%)
Operating Segments [Member] \| Clinical Research [Member]
Segment Reporting Information [Line Items]
Subtotal	$ 3,635,000	5,240,000
Change Increase (Decrease), Research and development expenses	$ (1,605,000)
Change Increase (Decrease), Subtotal, percentage	(30.60%)
Operating Segments [Member] \| Clinical Research [Member] \| OVATION 2 and MRD Trials [Member]
Segment Reporting Information [Line Items]
Subtotal	$ 402,000	1,386,000
Change Increase (Decrease), Research and development expenses	$ (984,000)
Change Increase (Decrease), Subtotal, percentage	(71.10%)
Operating Segments [Member] \| Clinical Research [Member] \| Ovation Three [Member]
Segment Reporting Information [Line Items]
Subtotal	$ 1,313,000
Change Increase (Decrease), Research and development expenses	$ 1,313,000
Change Increase (Decrease), Subtotal, percentage
Operating Segments [Member] \| Clinical Research [Member] \| Placcine Vaccine [Member]
Segment Reporting Information [Line Items]
Subtotal	$ 10,000	1,420,000
Change Increase (Decrease), Research and development expenses	$ (1,410,000)
Change Increase (Decrease), Subtotal, percentage	(99.30%)
Operating Segments [Member] \| Clinical Research [Member] \| Other Clinical and Regulatory [Member]
Segment Reporting Information [Line Items]
Subtotal	$ 1,910,000	2,434,000
Change Increase (Decrease), Research and development expenses	$ (524,000)
Change Increase (Decrease), Subtotal, percentage	(21.50%)
Operating Segments [Member] \| Non-Clinical R&D and CMC [Member]
Segment Reporting Information [Line Items]
Subtotal	$ 4,146,000	6,399,000
Change Increase (Decrease), Research and development expenses	$ (2,253,000)
Change Increase (Decrease), Subtotal, percentage	(35.20%)
Operating Segments [Member] \| Non-Clinical R&D and CMC [Member] \| Placcine Vaccine [Member]
Segment Reporting Information [Line Items]
Subtotal		2,554,000
Change Increase (Decrease), Research and development expenses	$ (2,554,000)
Change Increase (Decrease), Subtotal, percentage	(100.00%)
Operating Segments [Member] \| Non-Clinical R&D and CMC [Member] \| Ovation [Member]
Segment Reporting Information [Line Items]
Subtotal	$ 2,999,000	1,819,000
Change Increase (Decrease), Research and development expenses	$ 1,180,000
Change Increase (Decrease), Subtotal, percentage	64.90%
Operating Segments [Member] \| Non-Clinical R&D and CMC [Member] \| Manufacturing (CMC) [Member]
Segment Reporting Information [Line Items]
Subtotal	$ 1,147,000	$ 2,026,000
Change Increase (Decrease), Research and development expenses	$ (879,000)
Change Increase (Decrease), Subtotal, percentage	(43.40%)

FINANCIAL CONDITION AND GOING CONCERN UNCERTAINTY

12 Months Ended

Dec. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

FINANCIAL CONDITION AND GOING CONCERN UNCERTAINTY

2. FINANCIAL CONDITION AND GOING CONCERN UNCERTAINTY

Since inception, the Company has incurred substantial operating losses, principally from expenses associated with the Company’s research and development programs, clinical trials conducted in connection with the Company’s drug candidates, and applications and submissions to the Federal Drug Agency. The Company has not generated significant revenue and has incurred significant net losses in each year since inception. For the year ended December 31, 2025, the Company had a net loss of $14.5 million and used $13.9 million to fund operations. As of December 31, 2025, the Company has incurred approximately $421 million of cumulative net losses. As of December 31, 2025, the Company had $8.8 million in cash and cash equivalents and short-term investments. The Company has substantial future capital requirements to continue its research and development activities and advance its drug candidates through various development stages. The Company believes these expenditures are essential for the commercialization of its drug candidates and technologies.

The Company expects its operating losses to continue for the foreseeable future as it continues its product development efforts, and when it undertakes marketing and sales activities. The Company’s ability to achieve profitability is dependent upon its ability to obtain governmental approvals, manufacture, and market and sell its new drug candidates. There can be no assurance that the Company will be able to commercialize its technology successfully or that profitability will ever be achieved. The Company expects that its operating results will fluctuate significantly in the future and will depend on a number of factors, many of which are outside the Company’s control.

The Company’s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the U.S. and worldwide resulting from the Russian invasion of Ukraine and the unrest in the Middle East as well as other parts of the world. The Company continues to monitor its operating activities in light of these events, and it is possible that these events could result in a variety of risks to the business. The specific impact, if any, is not readily determinable as of the date of these consolidated financial statements.

The Company has based its estimates on assumptions that may prove to be wrong. The Company may need to obtain additional funds sooner or in greater amounts than it currently anticipates. Potential sources of financing include strategic relationships, public or private sales of the Company’s shares or debt and other sources. If the Company raises funds by selling additional shares of common stock or other securities convertible into common stock, the ownership interest of existing stockholders may be diluted.

The actual amount of funds the Company will need to operate is subject to many factors, some of which are beyond the Company’s control. These factors include the progress of research activities; the number and scope of research programs; the progress of preclinical and clinical development activities; the progress of the development efforts of parties with whom the Company has entered into research and development agreements; the costs associated with additional clinical trials of drug candidates; the ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements; the ability to achieve milestones under licensing arrangements; the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and the costs and timing of regulatory approvals.

The consolidated financial statements have been prepared on the going concern basis. In making this assessment, management conducted a comprehensive review of the Company’s business plan including, but not limited to:

	●	the Company’s financial position for the year ended December 31, 2025;

	●	significant events and transactions the Company may have entered into since December 31, 2025;

	●	the Company’s cash flow and cash usage forecasts for the period one year from the issuance date of this Annual Report on Form 10-K;

	●	the Company’s capitalization structure including common stock outstanding and common stock issuable on exercise of warrants and equity awards, and other common stock issuable under equity plans; and

	●	continued support of the Company’s stockholders.

As a result of the uncertainties involved in our business, we are unable to estimate the duration and completion costs of our research and development projects or when, if ever, and to what extent we will receive cash inflows from the commercialization and sale of a product. Our inability to complete our research and development projects in a timely manner or our failure to enter into collaborative agreements, when appropriate, could significantly increase our capital requirements and could adversely impact our liquidity. These uncertainties could force us to seek additional, external sources of financing from time to time in order to continue with our business strategy. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business. Our estimated future capital requirements are uncertain and could change materially as a result of many factors, including the progress of our research, development, clinical, manufacturing, and commercialization activities.

Management has determined the Company has suffered recurring losses from operations and has an accumulated deficit that raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance date of this Annual Report on Form 10-K. The report of our independent registered public accounting firm for the year ended December 31, 2025 includes an explanatory paragraph, which expresses substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of the uncertainty.

A fundamental component of the ability to continue as a going concern is the Company’s ability to raise capital as required, as to which no assurances can be provided. To address the additional funding requirements of the Company, management has undertaken the following initiatives:

	●	it has assessed its current expenditures and will be reducing the current spending requirements where necessary;

	●	it will pursue additional capital funding in the public and private markets through equity sales and/or debt facilities;

	●	it will pursue possible partnerships and collaborations; and

	●	it will pursue potential out licensing for its drug candidates.

Our ability to continue as a going concern may depend on our ability to raise additional capital, attain further operating efficiencies, reduce expenditures, and ultimately, to generate revenue. There are no assurances that these future funding and operating efforts will be successful. If management is unsuccessful in these efforts, our current capital is not expected to be sufficient to fund our operations for the next twelve months.

Pay vs Performance Disclosure - USD ($)	12 Months Ended
Pay vs Performance Disclosure - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (14,495,028)	$ (18,620,242)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (24)(d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Consolidated Statement of Changes in Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock, Common [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2023	$ 6,266	$ 401,588,570	$ (85,188)	$ 60,796	$ (388,182,802)	$ 13,387,642
Balance, shares at Dec. 31, 2023	626,654
Balance, shares at Dec. 31, 2023			2
Net loss					(18,620,242)	(18,620,242)
Sale of equity through equity financing facilities	$ 3,393	9,057,045				9,060,438
Sale of equity through equity financing facilities, shares	339,251
Issuance of stock upon vesting of restricted shares	$ 8	113				121
Issuance of stock upon vesting of restricted shares, shares	807
Stock-based compensation expense		477,135				477,135
Realized and unrealized gains, net, on investment securities				(60,796)		(60,796)
Balance at Dec. 31, 2024	$ 9,667	411,122,863	$ (85,188)		(406,803,044)	$ 4,244,298
Balance, shares at Dec. 31, 2024	966,712
Balance, shares at Dec. 31, 2024			2			2
Net loss					(14,495,028)	$ (14,495,028)
Effect of reverse stock split	$ 704					704
Effect of reverse stock split, shares	70,448
Stock dividend, net of offering costs	$ 3,304	(13,581)				(10,277)
Stock dividend, net of offering costs, shares	330,397
Sale of equity through equity financing facilities	$ 15,562	13,612,508				13,628,070
Sale of equity through equity financing facilities, shares	1,556,129
Issuance of common stock upon exercise of common stock warrants	$ 4,826	3,462,869				3,467,695
Issuance of common stock upon exercise of common stock warrants, shares	482,550
Shares issued in exchange for services	$ 108	98,932				99,040
Shares issued in exchange for services, shares	10,767
Issuance of stock upon vesting of restricted shares	$ 26					26
Issuance of stock upon vesting of restricted shares, shares	2,647
Stock-based compensation expense		127,348				127,348
Balance at Dec. 31, 2025	$ 34,197	$ 428,410,939	$ (85,188)		$ (421,298,072)	$ 7,061,876
Balance, shares at Dec. 31, 2025	3,419,650
Balance, shares at Dec. 31, 2025			2			2

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2025	Dec. 31, 2024
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	100,000	100,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	350,000,000	112,500,000
Common stock, shares issued	3,419,652	966,714
Common stock, shares outstanding	3,419,650	966,712
Treasury stock, shares	2	2

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2025

Income Tax Disclosure [Abstract]

SCHEDULE OF INCOME TAX PROVISION (BENEFIT)

	2025		2024
Federal
Current	$	-	$	-
Deferred		-		-
State and Local		-		-
Current		-		-
Deferred		-		-
Total	$	-	$	-

SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION

The reconciliation (ASU 2023-09 tabular format) of the U.S. federal statutory income tax rate to the Company’s effective tax rate for the year ended December 31, 2025 is as follows:

Reconciling Item				Tax Effected			% of Net Loss

Net Loss	$	(14,495,028	)	$	(3,043,956	)		21.00	%

Change in Valuation Allowance					1,215,757			(8.39	)
Federal statutory rate
State taxes, net of federal tax benefit
Permanent differences
True-Up
Rate Change
Deferred vs statutory rate

Nontaxable and Nondeductible items
Equity based comp					26,743			(0.18	)

Expired NOL’s
Federal					1,703,110			(11.75	)

Other Adjustments - Equity based comp adjustment					98,346			(0.68	)
Effective tax rate				$	-0-			- 0-	%

	2024
Federal statutory rate		21.00	%
State taxes, net of federal tax benefit (1)		8.40
Permanent differences		(2.74	)
True-Up		(0.07	)
Other		0.11
Rate Change		0.57
Deferred vs statutory rate		(0.75	)
Expiration of NOLs		(17.51	)
Change in valuation allowance and deferred rate change, net		(9.01	)
Effective tax rate		-0-	%

(1)

State taxes in New Jersey made up the majority (greater than 50%) of the tax effects in this category for 2024-2025.

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES

The components of the Company’s deferred tax asset as of December 31, 2025 and 2024 are as follows:

	2025			2024
	December 31,
	2025			2024
Net operating loss carryforwards	$	75,150,030		$	66,141,490
Section 174		-			6,482,099
Other deferred tax assets, net		1,628,991			2,010,744
Subtotal		76,779,021			74,634,333
Valuation allowance		(76,779,021	)		(74,634,333	)
Total deferred tax asset	$	-		$	-

PROPERTY AND EQUIPMENT (Tables)

12 Months Ended

Dec. 31, 2025

Property, Plant and Equipment [Abstract]

SCHEDULE OF PROPERTY AND EQUIPMENT

Property and equipment at December 31, 2025 and 2024 consist of the following:

SCHEDULE OF PROPERTY AND EQUIPMENT

	2025			2024
	December 31,
	2025			2024
Machinery and equipment (5-7 year life)	$	938,377		$	951,192
Furniture and fixtures (3-5 year life)		167,351			167,351
Leasehold improvements (5-7 year life)		700,149			619,024
Property and equipment gross		1,805,877			1,737,567
Less accumulated depreciation and amortization		(1,275,941	)		(1,196,295	)

Total	$	529,936		$	541,272

WARRANTS

12 Months Ended

Dec. 31, 2025

Warrants

WARRANTS

9. WARRANTS

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB ASC 480, Distinguishing Liabilities from Equity (“ASC 480”), and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock, among other conditions for equity classification.

This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. The Company has analyzed the Warrants issued in the July 2024 Offering and determined they are considered to be freestanding instruments and do not exhibit any of the characteristics in ASC 480 and therefore are not classified as liabilities under ASC 480. The Warrants meet all of the requirements for equity classification under ASC 815 and therefore are classified as equity.

Following is a summary of all warrant activity for the two years ended December 31, 2025:

SUMMARY OF WARRANT ACTIVITY

Warrants	Number of Warrants Issued			Weighted Average Exercise Price
Warrants outstanding at January 1, 2024		12,272		$	246.00

Warrants issued during 2024		383,333			26.09
Warrants expired during 2024		(381	)	$	154.57
Warrants outstanding and exercisable at December 31, 2024		395,224		$	32.74
Warrants issued during 2025		5,024,066		$	2.68
Warrants exercised during 2025 – cashless exchange		(223,946	)	$	-
Warrants exercised during 2025		(671,732	)	$	5.16
Warrants expired during 2025		(10,137	)	$	242.61
Warrants outstanding and exercisable at December 31, 2025		4,513,475		$	5.04

Weighted average remaining contractual terms (years)		4.2	{a}

{a}

Amount excludes ~1.6 million prefunded warrants from the December 2025 financing which have no expiration date.

OTHER ACCRUED LIABILITIES (Tables)

12 Months Ended

Dec. 31, 2025

Payables and Accruals [Abstract]

SCHEDULE OF OTHER ACCRUED LIABILITIES

Other accrued liabilities at December 31, 2025 and 2024 include the following:

SCHEDULE OF OTHER ACCRUED LIABILITIES

	2025		2024
	December 31,
	2025		2024
Amounts due to contract research organizations and other contractual agreements	$	1,001,210	$	1,048,036
Accrued payroll and related benefits		1,611,936		1,945,111
Professional fees, franchise taxes and other		211,500		40,600
Total	$	2,824,646	$	3,033,747

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Cash flows from operating activities:
Net loss	$ (14,495,028)	$ (18,620,242)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	291,908	240,175
Amortization of right-of-use assets	406,992	477,941
Realized losses, net, on investment securities		(61,983)
Stock-based compensation	127,374	477,256
Fair value of shares issued in exchange for services	99,040
Non-cash effect of reverse stock split	704
Realization of deferred income tax asset		1,280,385
Net changes in:
Advances, deposits, and other current assets	193,507	408,859
Accounts payable and accrued liabilities	(521,121)	(3,057,361)
Net cash used in operating activities	(13,896,624)	(18,854,970)
Cash flows from investing activities:
Purchases of investment securities		(57,174)
Proceeds from sale and maturity of investment securities		9,915,448
Purchases of property and equipment	(280,572)	(29,541)
Net cash (used in) provided by investing activities	(280,572)	9,828,733
Cash flows from financing activities:
Proceeds from sale of common stock equity, net of issuance costs	13,628,070	9,060,438
Proceeds from issuance of common stock upon exercise of warrants	3,467,695
Issuance costs of stock dividend	(10,277)
Net cash provided by financing activities	17,085,488	9,060,438
Net change in cash, cash equivalents	2,908,292	34,201
Cash and cash equivalents at the beginning of year	5,872,767	5,838,566
Cash and cash equivalents at the end of year	8,781,059	5,872,767
Non-Cash Investing and Financing Activities
Recognition of operating lease right-of-use asset and liability	$ 274,295

FINANCIAL CONDITION AND GOING CONCERN UNCERTAINTY (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 14,495,028	$ 18,620,242
Fund operation	13,896,624	18,854,970
Cumulated net losses	421,298,072	$ 406,803,044
Cash and cash equivalents, short-term investments	$ 8,800,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References + Details

COMMITMENTS AND CONTINGENCIES

12 Months Ended

Dec. 31, 2025

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

12. COMMITMENTS AND CONTINGENCIES

We are not currently a party to any material legal proceedings.